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ABSTRACT: A series of 3-substituted 1,5-diarylpyrroles
bearing a nitrooxyalkyl side chain linked to diﬀerent spacers
were designed. New classes of pyrrole-derived nitrooxyalkyl
inverse esters, carbonates, and ethers (7−10) as COX-2
selective inhibitors and NO donors were synthesized and are
herein reported. By taking into account the metabolic
conversion of nitrooxyalkyl ethers (9, 10) into corresponding
alcohols, derivatives 17 and 18 were also studied. Nitrooxy
derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective
COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-
inﬂammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by
interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and 1H- and 13C-NMR studies
performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these
molecules within the COX-2 active site to be assessed.
■ INTRODUCTION
Traditional nonsteroidal anti-inﬂammatory drugs (tNSAIDs)
represent the most widely prescribed, eﬃcacious, and cost-
eﬀective pharmacological treatment of rheumatologic and
inﬂammatory disorders.1 In addition, this class of drugs is
widely used to treat mild to moderate pain.2 Their therapeutic
eﬀects are mediated by the inhibition of cyclooxygenase (COX)
2, which is the most important COX isoform contributing to
prostanoid generation at inﬂammatory sites and spinal cord.3
Selective COX-2 inhibitors (coxibs) have been developed to
produce an eﬃcacy comparable to tNSAIDs while reducing
gastrointestinal (GI) related adverse events which are mainly
due to the inhibition of COX-1-derived cytoprotective
prostanoids in the GI tract.4,5 However, the use of tNSAIDs
and coxibs is associated with an increased risk of thrombotic
and renal adverse events.6 This is due to their inhibitory eﬀects
on the biosynthesis of vascular prostacyclin (PGI2), a powerful
platelet inhibitor and vasodilator, which is mainly derived from
the hemodynamic shear induced by COX-2.7 Recently, Yu et al.
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showed that vascular COX-2 deletion ends in the reduction of
the expression of endothelial nitric oxide (NO) synthase and
consequent release of NO.8 Similar to prostacyclin, NO is
endowed with important cardioprotective properties, such as
vasodilation and inhibition of platelet function.9 Suppression of
PGI2 formation due to inhibition of vascular COX-2 is suﬃcient
to account for the cardiovascular (CV) hazard from NSAIDs
(traditional and selective for COX-2),10 but it may be increased
by secondary mechanisms such as suppression of NO
production.8
These ﬁndings justify the need to develop NSAIDs endowed
with NO-releasing properties in order to mitigate their CV and
GI hazard. Indeed, the novel class of anti-inﬂammatory agents,
named COX-inhibiting nitric oxide donors (CINODs),
developed by linking a NO-releasing moiety to a tNSAID,
has been shown to have a more favorable clinical proﬁle than
the parent tNSAIDs in randomized clinical trials.11,12 This is
plausibly due to the property of CINODs to release NO which
may replace the functions of inhibited prostanoids by the
tNSAIDs.13
Naproxcinod, 4-(nitroxy)butyl-(S)-2-(6-methoxy-2-
naphthyl)propanoate is the ﬁrst drug of the CINODs, the
class of which is in advanced state of development.14 In
randomized clinical trials, naproxcinod showed an improved
safety proﬁle with respect to blood pressure (BP) and GI tract
compared to naproxen.15,16 Naproxcinod is the ester of
naproxen with 4-(nitroxy)butanol (NOBA) and undergoes
hydrolysis, mainly in the GI tract, leading to the release of
naproxen and the organic nitrate NOBA. The analgesic and
anti-inﬂammatory activities of naproxcinod are dependent on
released naproxen, while NOBA is the main source of NO (for
more details, see Supporting Information). A common pathway
for NO generation among naproxcinod, NO-ﬂurbiprofen (3, a
naproxcinod congener, Chart 1), and glyceryl trinitrate (GTN)
was recognized.17,18 NOBA, as well as GTN, is a relatively fast
NO-releasing compound, and the CV eﬀects are detected for a
maximum of 3 h after the administration with naproxcinod. On
the contrary, the analgesic and anti-inﬂammatory eﬀects of
naproxcinod are more extended because they depend on the
pharmacokinetics of naproxen which is characterized by a long
half-life (i.e., 17 h).19
Our research was focused on the development of a new class
of coxibs based on the diarylpyrrole scaﬀold20−22 and
subsequently on the search of NO-releasing compounds
endowed with strong analgesic and anti-inﬂammatory proper-
ties. For the sake of completeness, here we report the synthesis
and the biological evaluation of a series of 1,5-diarylpyrrole
nitrooxyalkyl congeners (7−10) as a further transformation of
the very recently reported nitrooxyalkyl esters (6).23,24 In the
title compounds diﬀerent linkers between the 1,5-diarylpyrrole
scaﬀold and the NO releasing moiety were introduced. Thus,
O2NO-alkyl inverse ester (7), carbonate (8), and ethers (9, 10)
were prepared and evaluated in vitro and in vivo in order to
disclose new chemical entities useful in the long term treatment
of osteoarthritis (OA) with reduced GI and mainly CV adverse
eﬀects (Chart 2). In particular, nitrooxyalkyl ethers 9 and 10
were designed with the aim to prevent the hydrolysis of the side
chain, leading to compounds with the inhibitory activity toward
COX-2 and NO releasing property in the same molecule.
Conversely, with regard to the series of nitrooxyalkyl esters 6,
inhibitory activity toward COX-2 and the NO-releasing
property was retained in two diﬀerent parts of the molecule.
These esters, however, showed almost the same liability to
esterase previously described for naproxcinod and NO-
ﬂurbiprofen.
■ CHEMISTRY
As is sketched in Scheme 1, hydroxyethyl derivative 11a was the
common starting material for the synthesis of most of the title
Chart 1. Structures of Reference Compounds
Chart 2. Structures of 1,5-Diarylpyrrole Nitrooxyalkyl
Congeners 7−10
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compounds, and it was prepared in gram scale following the
previously-reported procedure.20,21 The condensation of
alcohol 11a with 4-nitroxybutanoic acid (see Supporting
Information) in the presence of EDC and DMAP gave
nitrooxyalkyl inverse ester 7. A diﬀerent activation of 11a was
requested for the synthesis of compounds 8 and 13. So
compound 11a was condensed with CDI (1,1′-carbon-
yldiimidazole) to give imidazocarboxylate 14 which by reaction
with hydroxypropan nitrate (see Supporting Information) in
dry pyridine and in the presence of 1,8-diazabicyclo[5.4.0]-
undec-7-ene (DBU) aﬀorded nitrooxyalkyl carbonate 8. The
transformation of 11a into the corresponding mesyl chloride 12
and further reaction with (Bu4N)NO3 in toluene at reﬂux gave
compound 13. This can be regarded as the simplest among the
nitroesters designed. The synthesis of nitrooxyalkyl ethers 9a−
d and 10a−c (Scheme 2) started with the alkylation of alcohols
11a−d with the proper hydroxyalkyl bromide in its
tetrahydropyranyl protected form (see Supporting Informa-
tion) to obtain compounds 15a−d and 16a−c which were
successively deprotected to give hydroxyalkyl ethers 17a−d and
18a−c. These ethers were then mesylated to give 19a−d and
20a−c and transformed into the expected nitrooxyalkyl ethers
9a−d and 10a−c following the same procedure used for the
preparation of compound 13.
■ RESULTS AND DISCUSSION
An in vitro cell culture (J774 murine macrophage) assay was
performed to evaluate the title compounds’ inhibitory potency
and selectivity on both COX-isoforms. Results showed that in
Scheme 1. Synthesis of Compounds 7, 8, and 13a
aReagents and conditions: (i) MsCl, DMAP, DIPEA, CH2Cl2, 3h, rt; (ii) (Bu4N)NO3, toluene, reﬂux; (iii) EDC, DIMAP, CH2Cl2, rt, 3 h; (iv) CDI,
dry Pyr, rt, 2 h; (v) dry Pyr, DBU, rt, 3 h.
Scheme 2. Synthesis of Compounds 9−11 and 15−20a
aReagents and conditions: (i) (Bu4N)Br, NaOH 50%, 70 °C, 20 h; (ii) PPTS, MeOH, 55 °C, 20 h; (iii) MsCl, DMAP, DIPEA, rt, 3 h; (iv)
(Bu4N)NO3, toluene, reﬂux, 1 h.
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very recently reported 1,5-diarylpyrrole derivatives 6,22−24 the
transformation of the nitrooxyalkyl ester moiety into a
nitrooxyalkyl ether group surprisingly led to very active
compounds (9 and 10). Some of these were endowed with
interesting NO-donating properties along with good and
selective COX-2 inhibitory activity ranging from low nanomolar
to micromolar values (Table 1). On the basis of the structure−
activity relationships (SARs), nitrooxyalkyl ethers 9a−d and
10a−c showed, on the whole, a better COX-2 inhibitory
activity with respect to the corresponding hydroxyalkyl
derivatives 17a−d and 18a−c. This result could be due to an
electronic interaction of the nitrate group or other interactions
of this moiety at the inner hydrophobic channel of the enzyme.
On the whole, compounds 9a−d and 10a−c appear equipotent
to the above-cited nitrooxyalkyl esters 6a−f. In particular, the
inhibitory activity of nitrooxyethyl derivatives 9a−c seems to be
independent of the presence and, to some extent, of the
position of the ﬂuorine atom but not of the number of
substituents. 3′,4′-Diﬂuoro derivative 9d is much less active
(0.920 μM) than the corresponding unsubstituted or
monohalogenated derivative 9a (0.017 μM) or 9b,c (0.027,
0.014 μM, respectively). A diﬀerent behavior may be found in
nitrooxypropyl ethers 10a−c. Only nonhalogenated derivative
10a still retains a potent COX-2 inhibitory activity (0.015 μM).
As for 3′- and 4′-ﬂuorinated derivatives 10b and 10c, their
inhibitory activity has partially decreased. This demonstrates
that the presence of the halogen in 4′-position (10c) is not fully
compatible with the lengthening of the spacer between the
O2NO group and the ethereal oxygen atom of the side chain.
This ﬁnding was not conﬁrmed when 3′- and 4′-ﬂuorinated
nitrooxypropyl esters 6e and 6f were taken into account. In
fact, both compounds showed a nanomolar COX-2 inhibitory
activity, compound 6d being the most active (0.0073 μM)
within the series. In this case, the three-carbon spacer, the
presence of the carbonyl group, and the 3′-position of the
ﬂuorine atom in the N1-phenyl ring seem to be the optimal
combination for a proﬁtable interaction with the active site of
the isoenzyme. Furthermore, among hydroxyethyl- and
hydroxypropyl ethers 17a−c and 18a−c, which could be
regarded as the metabolites of nitroesters 9 and 10,
respectively, compounds 17a−c showed an eﬃcacious and
selective COX-2 inhibitory activity spanning from 0.027 μM for
nonhalogenated compound 17a to 0.046 and 0.089 μM for the
3′-F and 4′-F derivatives, respectively. In this small series of
compounds the presence and the position of the ﬂuorine atom,
although not appearing to be detrimental to the retaining of the
COX-2 inhibitory activity, certainly decrease to some extent the
activity of unsubstituted alcohol 17a. On the contrary, within
the series of hydroxylpropyl ethers 18a−c, the absence of
ﬂuorine atom gives rise to the inactive compound 18a. The
presence of the halogen at 3′-position of the N1-phenyl ring of
the pyrrole nucleus in connection with the hydroxylpropyl
Table 1. In Vitro COX-1 and COX-2 Inhibitory Activity (J774 Murine Macrophage Assay) of Compounds 6, 9, 10, 17, and 18
IC50 (μM)
a
compd X n COX-1 COX-2 COX-1/COX-2 b
6ac H 2 >10 0.0430 >232.6
6bc H 3 >10 0.0420 >238.1
6cc 3-F 2 >10 0.0190 >526.3
6dc 3-F 3 1.1 0.0073 150.7
6ec 4-F 2 >10 0.0290 >344.8
6fc 4-F 3 >10 0.0372 >268.8
9a H 2 >10 0.0170 >588.2
9b 3-F 2 >10 0.0270 >357.1
9c 4-F 2 >10 0.0140 >714.3
9d 3,4-F2 2 >10 0.9200 >10.9
10a H 3 >10 0.0150 >666.7
10b 3-F 3 2.9 0.0230 126.1
10c 4-F 3 >10 0.1900 >52.6
17a H 2 >10 0.0270 >370.4
17b 3-F 2 >10 0.0460 >217.4
17c 4-F 2 >10 0.0890 >112.3
17d 3,4-F2 2 >10 0.4200 >23.8
18a H 3 >10 8.9900 >1.11
18b 3-F 3 3.7 0.2400 15.4
18c 4-F 3 >10 0.9400 >10.6
aResults are expressed as the mean (n = 3 experiments) of the % inhibition of PGE2 production by test compounds with respect to control samples.
The IC50 values were calculated by the GraphPad Instat program. Data ﬁt was obtained by means of the sigmoidal dose−response equation (variable
slope) (GraphPad software). bIn vitro COX-2 selectivity index [IC50(COX-1)/IC50(COX-2)].
cSee ref 24.
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chain seems to be decisive for the strong COX-2 inhibitory
activity. This inhibitory activity drastically decreases when the
ﬂuorine atom is shifted from position 3′ to 4′. As for O2NO-
alkyl inverse ester (7) and carbonate (8), these compounds
were found to be devoid of both activities, being unable to
release NO in an eﬃcient way and lacking at the same time the
COX-2 inhibitory activity, unlike what happens for compounds
6, 9, and 10. This diﬀerent behavior may be attributed to the
diversity of the functional group inserted as linker between the
pyrrole scaﬀold of compounds 7 and 8 and the nitroester
moiety. As a result, its side chains do not seem to have the right
stereoelectronic requisites for a proﬁtable interaction with the
isoenzyme. Compounds 9a−d and 10a−c were further
evaluated to assess their eﬃcacy and potency in determining
NO-vasorelaxing responses in a suitable experimental model of
vascular smooth muscle and, in particular, in endothelium-
denuded rat aortic rings. In this experimental approach, ﬁve of
the seven nitrooxyalkyl derivatives exhibited vasorelaxing
eﬀects. In particular, compounds 9a−d and 10a evoked a
concentration-dependent relaxation of the vascular smooth
muscle with potency levels of around 10 μM and eﬃcacy
parameters ranging from 43% to 65% (Table 2). Only
compounds 10b and 10c showed negligible levels of vaso-
relaxing eﬃcacy (<20%). The experiments carried out in the
presence of guanylate cyclase (GC) inhibitor 1H-[1,2,4]-
oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) conﬁrmed that the
vasorelaxing eﬀects were due to the release of NO. The eﬀect of
ODQ in fact signiﬁcantly antagonized the vasodilator responses
evoked by nitrooxy derivatives 9a−d and 10a (Table 2).
Previous experiments also showed that corresponding hydrox-
yalkyl derivatives 17a−d and 18a−c were devoid of signiﬁcant
vasorelaxing eﬀects (data not shown). This result further
indicated that such a pharmacodynamic feature is due to the
nitrooxy group and to its probable biotransformation to NO.
Consistent with the data emerged in previous studies,23,24 the
present experimental results indicate some relevant structural
aspects capable of inﬂuencing the vasorelaxing eﬀects (i.e., the
NO-releasing process). In particular, it can be observed again
that the length of the alkyl chain bearing the nitrooxy group
signiﬁcantly aﬀects the pharmacological behavior. Indeed, the
nitrooxyethyl ethers (two-carbon alkyl chain) exhibit higher
levels of vasorelaxing eﬀects than those shown by the
corresponding nitrooxypropyl ethers (three-carbon alkyl
chain). This is clearly evident from the direct comparison of
the couples of analogues 9a vs 10a, 9b vs 10b, and 9c vs 10c
(Table 2). It is noted that glyceryl trinitrate (GTN), selected as
reference drug endowed with rapid NO-releasing properties,
showed strong vasorelaxing eﬀects, with higher levels of
vasorelaxing potency (Table 2). Such experimental evidence
suggests that the compounds herein reported ensure a NO
release slower than GTN, thus acting as a “modulated” NO
donor. Thus, we have identiﬁed novel hybrid compounds
endowed with selective COX-2 inhibitory activity, important
for analgesic and anti-inﬂammatory eﬃcacy, and slow NO-
releasing properties that may translate into prolonged
protective eﬀects for the cardiovascular system.25
On the basis of their very encouraging COX-2 inhibitory
activity evidenced in the in vitro tests, compounds 9a−d, 17a−
d, and 18a were then selected and submitted to further
pharmacological tests to assess their in vivo anti-inﬂammatory
and antinociceptive activities. For this purpose compound
eﬀects were evaluated both in a chemical visceral pain model,
induced by the intraperitoneal injection of acetic acid (Writhing
test), and in the carrageenan-induced inﬂammatory pain model
(Tables 3 and 4). In Table 3 the analgesic eﬀect of compounds
9a−d, 10a, 17a−d, and 18a compared to that of celecoxib (as
reference drug), evaluated as the number of abdominal
constrictions induced by intraperitoneal acetic acid, is reported.
For each molecule a dose−response curve has been performed.
All compounds exhibited an analgesic eﬀect. The minimal dose
able to revert the painful condition was 10 mg/kg po for 9a, 9c,
and 17a, 20 mg/kg for 9d, 10a, 17b,d, 18a, and 40 mg kg−1 for
9b and 17c. Celecoxib was able to increase the pain threshold
starting from 3 mg/kg.
Moreover, these compounds were assayed in rats to assess
their eﬀects on pain threshold alteration and edema induced by
carrageenan. Four hours after the intraplantar administration of
carrageenan in the paw, all inﬂammatory signs were observed
(paw swelling hyperemia and hyperalgesia). The paw pressure
test was used to measure pain. All molecules showed a
statistically signiﬁcant capability to block the painful condition
caused by the strong inﬂammatory agent in the range between
30 and 120 min after administration (Table 4). Thirty minutes
after a 20 mg/kg po administration, all compounds showed
good activity against carrageenan-induced hyperalgesia. This
result was comparable to that obtained with celecoxib (10 mg/
kg po). Moreover, with the exception of 9b and 9d, for all
compounds, at the higher tested dose, the persistence of the
antihyperalgesic activity after the injection was longer than 60
min. Compounds 9a, 9c, 10a, 17c, and 17d exhibited their
eﬃcacy up to 120 min after treatment.
In the carrageenan-induced inﬂammatory pain model the
measure of the paw volume allows discrimination of the
analgesic property from the anti-inﬂammatory one. In Table 4
is shown a signiﬁcant paw edema decrease 60 min after the
administration of all the investigated compounds. These data
strongly suggest the anti-inﬂammatory eﬀect as the base of the
analgesic mechanism of these molecules. Finally, the eﬃcacy of
compounds 9c and 17c was also evaluated in the rat
osteoarthritis model induced by the intra-articular injection of
Table 2. Evaluation of Eﬃcacy and Potency in Determining
NO-Dependent Vasorelaxing Responses of 9a−d, 10a−c,
and Gliceryl Trinitrate (GTN)
compd X n Emax
a pIC50
b
6ac H 2 65 ± 2 5.76 ± 0.08
6bc H 3 44 ± 8 ≤5
6cc 3-F 2 69 ± 4 6.48 ± 0.06
6dc 3-F 3 39 ± 1 ≤5
6ec 4-F 2 58 ± 5 5.47 ± 0.07
6fc 4-F 3 41 ± 2 ≤5
9a H 2 65 ± 3 5.22 ± 0.03
9b 3-F 2 60 ± 4 5.32 ± 0.05
9c 4-F 2 49 ± 4 ≤5
9d 3,4-F2 2 43 ± 6 ≤5
10a H 3 48 ± 5 ≤5
10b 3-F 3 na
10c 4-F 3 na
GTN 93 ± 2 6.90 ± 0.07
aEmax represents the vasorelaxing eﬃcacy, expressed as a % of the
vasoconstriction induced by the preadministration of KCl. bThe
parameter of potency is expressed as pIC50, representing −log of the
molar concentration capable of inducing a vasorelaxing eﬀect = 50% of
Emax.
cSee ref 24.
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monoiodoacetate (MIA). The injection of MIA in the knee
joint induces necrosis of condrocytes with decrease of cartilage
thickness and osteolysis.26 Kobayashi et al. showed that MIA is
able to disorganize condrocytes and to promote cartilage
erosion.27 These alterations are comparable with joint damages
typical of humans aﬀected by osteoarthritis.28−30 An amount of
20 mg kg−1 compound 9c or 17c was administered po twice
daily for 13 days starting from the day of MIA injection to
evaluate a preventive eﬀect. On day 14, when pain and the
degenerative articular process are overt, the pain threshold was
measured by paw pressure test (Table 5). The repeated
treatment with 9c or 17c signiﬁcantly prevented MIA-
dependent hyperalgesia (before treatment). A further com-
pound administration (after treatment, 30 min) did not induce
an additive acute antihyperalgesic eﬀect, suggesting that a
repeated treatment with the present anti-inﬂammatory
compounds could be able to prevent the joint damage and,
consequently, pain.28−31
Study of cartilage catabolism in culture has received
considerable attention over the past 3 decades because of the
pivotal role that this process plays in cartilage degeneration in
arthritis.32 From realization that such degeneration is driven by
cytokines, cartilage organ culture became a standard technique
for monitoring the eﬀects of cytokines on chondrocytes
metabolism. Under such conditions proteoglycans degradation
was found to be an early event, with the glycosaminoglycans
(GAG) rich degradation products being readily released from
the tissue into the culture medium.33 Therefore, following the
assessment of their anti-inﬂammatory and antinociceptive
activity, nitrooxyethyl ether derivative 9c and its metabolite
17c were selected and tested to determine their cartilage
protective properties. The test consisted of quantitation of
GAG in the form of aggrecan fragments released from bovine
articular cartilage of the metacarpophalangeal joints of the feet.
After being cultured according to the procedure reported by
Homandberg et al.34 (see Supporting Information), fragments
were challenged for 48 h with IL-1β (30 ng/mL) and
quantitation of GAG release was assessed by means of most
widely used Farndale’s colorimetric method.35 Results are
shown in Figure 1. Compounds 9c and 17c were able to inhibit
GAG release induced by IL-1β in a concentration-dependent
manner (IC50 of 1.5 and 33 μM, respectively). Treatment with
9c, 17c, or IL-1β did not aﬀect the viability of cell recovery
from cartilage. Our results show that compound 9c can
contribute to the reduction of IL-1β-dependent cartilage
catabolism both by the inhibition of prostanoid biosynthesis
and by NO releasing properties. Neverthless, the release of NO
by 9c seems to play a major role. This assumption is based on
the fact that compound 17c, which was unable to release NO,
was found to be 22-fold less potent than the parent compound,
although its activity in inhibiting COX-2 activity in murine J774
cells was comparable to that of 9c.
With the aim of assessing COX-2 selectivity, a human whole
blood (HWB) assay was carried out on selected compounds 9c
and 17c (nitrooxy ether and hydroxyethyl ether, respectively).
In particular, the assay was performed to predict the actual
extent of isozyme inhibition achievable in vivo by circulating
drug levels to consider the amount of variables potentially able
to aﬀect drug−enzyme interaction. As shown in Figure 2
(panels A and B) the concentration−response curves for
inhibition of COX-1 and COX-2 in human whole blood elicited
by 9c and 17c, respectively, were studied. Nitrooxy ether
derivative 9c and its NO-free metabolite 17c inhibited LPS-
induced whole blood PGE2 generation (COX-2 assay) in a
concentration-dependent fashion with IC50 values (Table 6)
signiﬁcantly comparable. The steepness of the curves by
calculating the Hill slope values was also studied. The 9c Hill
slope value was signiﬁcantly comparable to 1.0, which is typical
for a standard sigmoid concentration−response curve where
response (Y) is a function of the logarithm of compound
concentration (X). The Hill slope value of 17c was slightly, but
signiﬁcantly, less than 1.0 (Table 6). As has been previously
reported,36 NSAIDs that inhibit COX activity with a Hill slope
value of 1.0 are freely reversible and exhibit simple competitive
inhibition. Since the administration of an analgesic dose of
NSAIDs is associated with a 80% inhibition of whole blood
COX-2 activity,37 the IC80 values for these compounds were
calculated. As shown in Table 6, compounds 9c and 17c
showed comparable IC80 values in inhibiting COX-2. Taken
together, these results suggest that nitrooxyethyl ether
derivative 9c and its metabolite 17c have a comparable and
potent inhibitory eﬀect on monocyte COX-2 activity of HWB.
Furthermore, 9c and 17c inhibited platelet COX-1 activity in a
concentration-dependent fashion (Figure 2, panels A and B);
however, 17c was slightly, but signiﬁcantly, more potent in the
inhibition of COX-1 rather than 9c (both at IC50 and IC80)
(Table 6). Interestingly, both compounds inhibited COX-1
Table 3. Dose−Response Results of Compounds 9a−d, 10a,
17a−d, and 18a in the Acetic Acid Writhing Testa
treatment no. mice dose per os (mg kg−1) no. writhes
saline 36 32.4 ± 1.9
9a 10 10 21.2 ± 3.0∧
9a 8 20 15.5 ± 3.6*
9b 8 10 32.5 ± 3.7
9b 8 20 30.3 ± 2.1
9b 8 40 25.3 ± 3.6*
9c 8 3 28.5 ± 3.2
9c 8 10 19.1 ± 2.7*
9c 8 20 15.2 ± 3.3*
9d 7 10 27.3 ± 2.5
9d 7 20 24.8 ± 3.0*
9d 7 40 25.6 ± 2.3*
10a 9 10 29.4 ± 3.0
10a 10 20 21.2 ± 3.0*
10a 8 40 26.8 ± 3.2∧
17a 8 10 21.2 ± 3.0*
17a 8 20 15.5 ± 3.6*
17b 8 10 29.4 ± 3.0
17b 8 20 26.8 ± 3.2∧
17b 8 40 17.3 ± 3.5*
17c 7 10 31.3 ± 2.7
17c 8 20 27.9 ± 3.6
17c 8 40 18.2 ± 3.1*
17d 9 10 32.3 ± 2.8
17d 8 20 26.3 ± 3.4∧
17d 8 40 17.3 ± 2.2*
18a 9 10 29.7 ± 3.4
18a 9 20 22.3 ± 2.5*
18a 7 40 21.5 ± 2.3*
celecoxib 10 1 25.6 ± 3.1*
celecoxib 11 3 15.4 ± 2.5*
celecoxib 15 10 11.3 ± 2.9*
aEach value represents the mean of at least seven mice: (∧) P < 0.05,
(∗) P < 0.01 in comparison with CMC treated group.
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activity with Hill slope values of >1.0 (Table 6), normally a
feature of steeper curves. A time-dependent COX inhibiting
eﬀect was observed by NSAIDs with Hill slope values of >1.0.36
Selectivity of 9c and 17c toward COX-2 was determined as
IC50 and IC80 ratios for the inhibition of whole blood COX-1
Table 4. Eﬀect of Compounds 9a−d, 10a, 17a−d, and 18a on Hyperalgesia and Edema Induced by Carrageenan in the Rat Paw
Pressure Testa
paw pressure in rats (g)
after treatment paw volume (mL)
pretreatment intraplantar treatment per os before treatment 30 min 60 min 120 min before treatment 60 min
saline saline 62.6 ± 2.4 61.5 ± 3.1 60.2 ± 3.3 62.9 ± 3.5 1.46 ± 0.05 1.42 ± 0.07
carrag saline 31.4 ± 3.4 34.8 ± 3.0 33.9 ± 3.7 31.4 ± 3.7 1.47 ± 0.07 2.48 ± 0.06
carrag 9a 20 33.9 ± 3.1 54.2 ± 3.1* 55.3 ± 3.5* 48.7 ± 3.7∧ 1.31 ± 0.09 1.45 ± 0.10*
carrag 9b 20 34.6 ± 3.0 43.9 ± 3.1∧ 40.7 ± 3.0 35.2 ± 3.5 1.58 ± 0.08 2.16 ± 0.09∧
carrag 9b 40 31.6 ± 2.7 47.3 ± 4.2* 41.0 ± 4.4 34.3 ± 4.1 1.55 ± 0.09 2.08 ± 0.07*
carrag 9c 10 34.1 ± 2.7 55.1 ± 4.7* 52.6 ± 4.0* 48.3 ± 5.2∧ 1.49 ± 0.08 1.87 ± 0.07*
carrag 9c 20 32.0 ± 3.5 56.8 ± 3.9* 49.2 ± 4.6* 43.8 ± 4.5∧ 1.53 ± 0.08 1.92 ± 0.08*
carrag 9d 20 32.7 ± 3.7 44.6 ± 4.0∧ 46.9 ± 4.2∧ 38.8 ± 3.5 1.54 ± 0.06 2.19 ± 0.07∧
carrag 9d 40 35.2 ± 3.1 49.5 ± 3.8* 42.5 ± 4.1 35.3 ± 3.8 1.48 ± 0.07 2.10 ± 0.08*
carrag 10a 20 32.9 ± 3.3 53.7 ± 3.4* 51.6 ± 3.2* 45.6 ± 3.4∧ 1.53 ± 0.06 1.80 ± 0.04*
carrag 17a 20 31.8 ± 3.2 56.6 ± 4.3* 49.2 ± 3.8∧ 37.8 ± 3.6 1.26 ± 0.05 1.34 ± 0.07*
carrag 17b 20 32.7 ± 3.9 46.9 ± 3.8∧ 48.6 ± 3.5∧ 37.2 ± 3.9 1.55 ± 0.08 2.46 ± 0.08
carrag 17b 40 33.5 ± 3.9 51.4 ± 3.0* 45.3 ± 4.4∧ 39.5 ± 4.0 1.49 ± 0.09 2.12 ± 0.06∧
carrag 17c 20 32.5 ± 3.4 46.8 ± 3.7* 38.7 ± 3.3 38.3 ± 3.9 1.57 ± 0.07 2.01 ± 0.09*
carrag 17c 40 30.5 ± 3.5 57.2 ± 4.6* 58.3 ± 4.5* 47.6 ± 4.4∧ 1.55 ± 0.09 1.95 ± 0.08*
carrag 17d 20 31.6 ± 2.8 43.6 ± 3.8∧ 46.7 ± 3.5∧ 41.4 ± 4.7 1.56 ± 0.08 2.16 ± 0.08∧
carrag 17d 40 34.1 ± 3.3 53.2 ± 3.4* 55.2 ± 4.2* 49.3 ± 3.6* 1.58 ± 0.09 1.96 ± 0.06*
carrag 18a 20 33.8 ± 3.8 52.9 ± 3.6* 50.3 ± 2.9* 46.6 ± 3.1∧ 1.47 ± 0.05 1.86 ± 0.04*
carrag celecoxib 3 31.7 ± 2.7 44.3 ± 3.8* 41.6 ± 3.2 40.7 ± 2.6 1.59 ± 0.08 2.35 ± 0.07
carrag celecoxib 10 33.5 ± 2.6 52.9 ± 3.1* 48.3 ± 3.4* 39.8 ± 3.1 1.50 ± 0.05 1.45 ± 0.06*
aThere were four rats per group: (∧) P < 0.05, (∗) P < 0.01 versus the carrageenan/saline-treated group; carrag = carrageenan.
Table 5. Eﬀect of Repeated Treatment with Compounds 9c
and 17c on Hyperalgesia Induced by Osteoarthritis in the
Paw Pressure Testa









saline CMC 61.2 ± 3.0 58.7 ± 2.9
MIAb CMC 32.6 ± 2.9 30.4 ± 3.1
MIAb 9c (20) 43.5 ± 2.9* 45.1 ± 3.7*
MIAb 17c (20) 49.7 ± 3.5* 51.2 ± 3.9*
aThere were four rats per group: (∗) P < 0.01 versus the MIA treated
rat. bMIA = monosodium iodoacetate.
Figure 1. Eﬀect of compounds 9c and 17c on glycosaminoglycans
(GAG) released from bovine articular cartilage challenged for 48h with
IL-1β (30 ng/mL). Results are expressed as percent of control (IL-1β
alone) (mean ± SEM, n = 3). EC50 (9c and 17c concentration that is
reduced by 50% IL-1β-induced GAG release) and its 95% conﬁdence
intervals (CI) are shown.
Figure 2. Eﬀects of compounds 9c and 17c on in vitro platelet COX-1
and monocyte COX-2 activity in human whole blood. Results are
expressed as average percentage of inhibition (N = 3−6, mean ±
SEM).
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and COX-2. As shown in Table 6, both compounds were 50-
fold more potent toward COX-2 than COX-1 at IC50. A lower
COX-2 selectivity was found at IC80.
In conclusion, 9c and its metabolite 17c are potent and
selective inhibitors of COX-2. Although further studies should
be performed, our data may suggest that 9c and 17c inhibited
COX-2, but not COX-1, in a time-dependent fashion.
Altogether our results oﬀer proof-of-concept that compounds
endowed with dual pharmacological activities, i.e., selective
COX-2 inhibition and NO-releasing properties, show analgesic
and anti-inﬂammatory eﬀects in experimental rodent models in
vivo. Our results indicate that COX-2 inhibition is the central
mechanism for obtaining analgesic and anti-inﬂammatory
eﬀects. Similarly, in randomized clinical trials naproxcinod has
been shown to cause comparable relief of the signs and
symptoms of OA.38 However, we showed in vitro that the NO-
releasing properties of novel compound 9c introduced an
additional protective eﬀect by preventing cartilage matrix
degradation compared to compound 17c which was unable
to release NO. Indeed, NO, at low concentrations, has been
previously reported to play protective roles in the joint.39
Molecular Modeling Simulations. To better understand
the inhibitor−enzyme interactions and to improve our
previously proposed mode of binding of NO donors and
COX-2 inhibitors 6,24 compounds 6d and 10b were submitted
to rigorous ab initio calculations along with molecular docking
and molecular dynamics simulations. In particular, compounds
6d and 10b were built starting from the X-ray crystallographic
data of 6c (Figure S1 in the Supporting Information) and then
optimized by means of the ab initio restricted Hartree−Fock
(RHF) method40 taking into account the generic nuclear
Overhauser eﬀect (NOE) constraints41 resulting from 1H-
NMR solution studies (see Supporting Information). The
partial atomic point charges of compounds 6d and 10b were
calculated by the RHF method40 and used in the following
molecular docking calculations. The binary complexes of
compounds 6d and 10b with isozyme COX-2 (PDB entry
6cox), obtained from ﬂexible docking simulations and
performed by means of Autodock 4.2,42 were subjected to an
extensive molecular dynamics study aimed at investigating (i)
the binding mode proﬁle of new derivatives, (ii) the stability of
the previously published binding mode24 of nitrooxyalkyl esters
6c and 6d, and (iii) the main intermolecular interactions based
on a large time-scale simulation. During 5 ns of molecular
dynamics simulations, the complexes showed a geometric stable
proﬁle according to which the binding mode of compound 6d
did not substantially diverge from the one previously
reported,24 conﬁrming the signiﬁcance of the docking results
obtained on that occasion. This is the reason why in the present
study only the main interactions between the lateral side chain
bearing the -ONO2 moiety of the 1,5-diarypyrrole derivatives
6d and 10b and the COX-2 active site were taken into account
and discussed. During the whole molecular dynamics,
compound 6d by means of the two oxygen atoms of the
carboxypropyl group can engage, permanently, a double
hydrogen bond interaction with ARG 120 and TYR 355.
Thus, the nitroester group is allowed to lie near SER 119,
favoring in this way an additional hydrogen bond interaction of
one of the oxygen atoms with the hydroxyl group of such an
amino acid (Figure 3).
When a 5 ns trajectory from a molecular dynamics simulation
(MD) of the complex of nitrooxypropyl ether 10b with the
active site of COX-2 is analyzed, the hydrogen bond interaction
between one of the oxygen atoms of the nitro group and SER
119 is completely lost in favor of a diﬀerent orientation of the
lateral side chain which seems to be no more extended than it
appears in compound 6d (Figure 5). In addition, the hydrogen
bond between ARG 120 and the ethereal oxygen of compound
10b is not permanently present during the MD simulation
(Figure 4).
On the whole, according to the molecular dynamics
simulations, it appears that the conformation of the lateral
side chain of the inhibitors along with the hydrogen bond
interaction with the SER 119 has to be considered responsible
for the diﬀerent COX-2 inhibitory activities of compounds 6d
and 10b, the IC50 being 7.3 and 23.0 nM, respectively. On the
other hand, compound 9d shows a diﬀerent binding mode with
respect to compounds 6d and 10b. In particular, compound 9d
is not able to form any hydrogen bond with SER 119 and the
Table 6. IC50 and IC80 Values, Hill Slopes, and COX-2 Selectivity of Compounds 9c and 17c in Human Whole Blood (HWB)
Assaysa
9c 17c
COX-2 COX-1 COX-2 COX-1
IC50 (μM) 0.64 (0.43−0.96) 31.24 (26.16−36.55) 0.40 (0.19−0.83) 20.00 (17.33−23.10)
Hill slope 1.10 (0.73−1.46) 1.85 (1.37−2.33) 0.79 (0.59−0.98) 2.24 (1.72−2.77)
IC50(COX-1)/IC50(COX-2)
b 50.00 50.00
IC80 (μM) 2.26 63.3 2.31 37.14
IC80(COX-1)/IC80(COX-2)
b 29.33 16.07
aFor IC50 values and Hill slopes, 95% conﬁdence intervals are shown in parentheses.
bSelectivities of compounds toward COX-2 were determined as
IC50 and IC80 ratios for HWBA-COX-1 and COX-2.
Figure 3. Snapshot of the molecular dynamics simulation of
nitrooxypropyl ester 6d into the COX-2 active site. The main residues
and the inhibitor are represented as licorice. Hydrogen bonds are
represented as blue dotted lines. For the sake of clarity, only the lateral
side chain interacting residues are displayed.
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polar contact to the ARG 120 is actually infrequent during the
molecular dynamics simulation studies. These diﬀerences, in
agreement with the biological data, are probably due to the
stereoelectronic eﬀects induced by the introduction of 3′,4′-
diﬂuoro substituents coupled to a short lateral side chain linker.
1H- and 13C-NMR Studies Performed on Compounds
6c,d, 9c, and 10b. NMR analysis has been done with the aim
of determining both dynamics and conformations of com-
pounds 6c,d, 9c, and 10b the atoms of which have been
numbered according to Figure 5. It is known that 13C R1 (R1 =
1/T1) relaxation rates are almost exclusively determined by
dipolar interactions with directly bonded or nearby protons,
thus allowing suitable delineations of the molecular dynam-
ics.43,44 The motional features of aromatic carbons were
considered ﬁrst, since they have fewer degrees of freedom
than side chain carbons. For ring B of compounds 6c, 6d, and
10b, the relaxation rate of C14 was faster than those of the other
carbon atoms, suggesting that C11−C14 is the main rotation axis
for this aromatic ring. The relaxation rates of C12, C15, and C16
were very similar so that an anisotropic model consisting of
rotational reorientation around the main rotation axis with
some degree of internal motion could be applied45 (eq 1 with A



































In eq 1, τc,B is the main rotation correlation time, τg,B is the
correlation time for librational motions of aromatic ring B, rCH
is the length of the C−H bond, n is the number of protons
attached to the carbon under consideration, and γ is the angle
between the main rotation axis and the C−H vector. The main
correlation time, τc,B, can be calculated by considering the
relaxation rate R1 (=1/T1) of C14,. Since the C14−H14 vector















This holds for a pure dipole−dipole relaxation mechanism
within the extremely narrow region.46 As all protonated carbons
exhibit maximum 13C−1H nuclear Overhauser eﬀects, eq 2 was
used to extract τc,B. τg,B was then obtained by applying eq 1.
The same analysis holds for ring A: the relaxation rates of C7
and C8 are very similar and the main rotation axis is C6−C9, as
is expected for a para-disubstituted benzene.
Thus, the same anisotropic model can be applied. However,
it is impossible to calculate τc,A, the main correlation time of
ring A, from the relaxation rates of carbon atoms. Proton
relaxation rates must be used. Indeed, the H7−H8 vector is
parallel to the main axis C6−C9, and by taking advantage of
double selective and selective relaxation rates, eq 3 can be



















Figure 4. Snapshot of the molecular dynamics simulation of
nitrooxypropyl ether 10b into the COX-2 cyclooxygenase site. The
main residues and the inhibitor are represented as licorice. Hydrogen
bonds are represented as blue dotted lines. For the sake of clarity, only
the lateral side chain interacting residues are displayed.
Figure 5. Numbering of atoms of compounds selected for 1H- and 13C-NMR studies.
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where r7,8 is the H7−H8 interproton distance (it has been
determined from neutron scattering data that r7,8 = 2.45 Å).
47
Then from eq 3 the τc,A is obtained and by applying eq 1 again,
the corresponding correlation times for librational motions
(τg,A) were calculated. This last approach should also have been
applied to ring B of compound 9c (in this compound both
benzene rings are para-disubstituted). However, the proton
resonances of H12 and H13 overlap and it was impossible to
evaluate the corresponding relevant proton relaxation rates.
The correlation times of the side chain carbons and of C-4
(pyrrole ring) were evaluated from eq 2 (see Table 7).
The analysis of the data show that the main correlation times
within each compound are similar or very similar to each other
and to the correlation time of C-4 (pyrrole ring). Thus, this
result suggested that the motions within the aromatic moieties
of these compounds are correlated, and consequently a mean
main conformation is present. As expected, the motional
freedom increases (τc values decreases) along the side chains.
However, the compounds with the shorter ethyl side chain (6c
and 9c) have greater conformational freedom than the
corresponding compounds with propyl side chains (6d and
10b). The conformational analysis has been performed by
exploiting qualitative analysis of 1D NOE (diﬀerence experi-
ments; for further details see Supporting Information) and 2D
NOE (NOESY) experiments.48,49 The NOE experiments have
been performed in 0.1 and 0.01 M solutions. Since the results
are very similar, it can be safely assumed that the NOE eﬀect is
intramolecular. Moreover, the distance between H4 and H7
protons in all compounds could be evaluated by quantitative
1D NOE data analysis50 (Table 8). This distance r4,7 ranges
from 2.5 Å (9c) to 2.6 Å (6d and 10b) and 2.7 Å (6c). The
same distances have been determined by analysis of proton
relaxation rates (see Supporting Information), and as is shown
in Table 8, their values are very close to the corresponding
values determined by 1D NOE experiments.
In addition to these distances, r4,7 have values that are close
to each other in the whole series of compounds. Also, NOE
eﬀects have been found between the protons of the methyl
bonded to the C2 of pyrrole ring and the protons of ring B: H12
(9c) or H12 and H16 (6c, 6d, and 10b). These results conﬁrmed
the evidence of aromatic moieties with restricted internal
motions with a preferred mean main conformation that is
practically the same in all these molecules. Thus, the core of
these molecules is characterized by almost the same dynamical
and conformational features independent of diﬀerent side
chains. The analysis of NOE data also allowed the delineation
of important conformational details of the side chains. We ﬁrst
consider the compounds with the ester function in their side
chain (6c and 6d). In both these compounds there is a NOE
eﬀect between H4 and the ﬁrst methylene group (H17) of the
side chain. In 6c there are no NOE eﬀects between H19 and H20
methylene protons and other protons of the molecule; the
chain folds away from the aromatic moiety and H17. In 6d NOE
eﬀects have been found between H19 and H20 methylene
protons and the protons (H22) of the methyl group bonded to
C2. This chain presents a partial folding toward the methyl
group. The NOE analysis also showed signiﬁcant diﬀerences in
the mean main conformations of the two compounds with the
ether function in their side chain (9c and 10b). An unexpected
NOE eﬀect was found for compound 9c. It involved side chain
protons H16 and H17. The chain simply moves straight away
from the aromatic moiety. In 10b there are NOE eﬀects
between the protons of the ﬁrst two methylene groups (H17
and H18) and H4 while the protons of the propyl moiety show
no NOE eﬀects with other protons of the molecule. The chain
presents an initial folding toward H4 and then moves straight
away. Further insight into the conformations of the side chains
was obtained by considering the coupling system of their
protons (see Supporting Information, in particular Table S1
and Figure S4). In compounds 9c and 10b the protons of the
Table 7. Correlation Times τc and τg (s) of Compounds 6c,d, 9c, and 10b
parameter 6c 6d 9c 10b
Aromatic Rings
τc (A) 0.68 × 10
−12 0.84 × 10−12 0.76 × 10−12 0.68 × 10−12
τg (A) 0.38 × 10
−12 0.19 × 10−12 0.48 × 10−12 0.25 × 10−12
τc (B) 0.63 × 10
−12 0.84 × 10−12 1.10 × 10−12
τg (B) 0.48 × 10
−12 0.32 × 10−12 0.39 × 10−12
τc (C-4) 0.64 × 10
−12 0.70 × 10−12 0.67 × 10−12 0.79 × 10−12
Methylene Groups
τc (C-15) 0.31 × 10
−12
τc(C-16) 0.24 × 10
−12
τc (C-17) 0.34 × 10
−12 0.41 × 10−12 0.18 × 10−12 0.46 × 10−12
τc (C-18) 0.22 × 10
−12 0.38 × 10−12
τc (C-19) 0.14 × 10
−12 0.18 × 10−12 0.24 × 10−12
τc (C-20) 0.18 × 10
−12 0.20 × 10−12 0.23 × 10−12
τc (C-21) 0.14 × 10
−12 0.16 × 10−12
Methyl Groups
τc (C-10) 0.12 × 10
−12 0.14 × 10−12 0.16 × 10−12 0.19 × 10−12
τc (C-19) 0.08 × 10
−12
τc (C-21) 0.05 × 10
−12
τc (C-22) 0.07 × 10
−12 0.05 × 10−12
Table 8. Proton−Proton Distances r (Å) in Compounds
6c,d, 9c, and 10b Estimated from Relaxation Rates (a) and
1H{1H}NOEs (b) (0.1 M) and Corresponding Dihedral
Angles θ (deg) between Ring A and Pyrrole Ring
6c 6d 9c 10b
parameter a b a b a b a b
r4,7 2.55 2.7 2.6 2.6 2.45 2.5 2.5 2.6
θ 35 44 38 38 33 36 32 38
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ﬁrst two methylene groups give rise to two triplets as expected
for protons of alkyl chains that adopt the usual all-trans
conformations. The same situation is presented by the protons
of the propyl chain of compounds 6d and 10b (H19, H20, and
H21), two triplets (H19 and H21) and a quintet (H20)
corresponding once again to the all-trans conformation. The
situation is completely diﬀerent for the ethyl moieties of
compounds 6c (H19 and H20) and 9c (H17 and H18). These
protons give complex multiplets, and this means that the
protons within each methylene group are not equivalent. This
in turn means that the conformations are gauche conformations
around the bonds C19−C20 (6c) and C17−C18 (9c). In
conclusion, these molecules have an aromatic moiety that
does not diﬀer in dynamics and conformation from one
compound to the other while the side chains stemming out of
the aromatic core have their own dynamics and very diﬀerent
conformations (they explore diﬀerent conformational spaces).
This diﬀerent behavior of the side chains is likely to be
responsible for the ﬁne-tuning and consequently diﬀerent
response in their interactions with the receptor.
A representation of the mean main conformations of
compounds 6c,d, 9c, and 10b, as was deduced from NMR
analysis, is shown in Figure 6.
■ CONCLUSION
The combination of a COX-2 inhibitor with an appropriate
NO-donor moiety can be the bases for the development of new
drugs endowed with strong analgesic and anti-inﬂammatory
properties. With no adverse eﬀects on the GI and with an
appropriate CV and renal safety, they might be used in long-
term treatments and in the elderly population. Obtaining a drug
acting as both COX-2 inhibitor and NO donor without being
hydrolyzed was pursued in this work in order to provide new
drugs endowed with the same pharmacokinetic properties for
both the COX inhibitor and the NO-donor moieties which
could provide COX-2 inhibition and NO suitable concen-
trations at the same time and in the same compartment. In
addition, particular attention to NO-releasing properties of the
obtained compounds was given in order to improve CV-
protective properties and to take advantage of the above-
discussed favorable eﬀects exerted by low NO concentrations
on inﬂammatory and cartilage degradation processes. In
particular, ﬁve of the seven nitrooxyalkyl derivatives exhibited
vasorelaxing eﬀects. Among them, nitrooxyethyl ethers (two-
carbon alkyl chain), 9a−c, show vasorelaxing eﬀect higher than
that shown by the corresponding nitrooxypropyl ethers (three-
carbon alkyl chain). By taking into account the metabolic
conversion of nitrooxyalkyl ethers (9 and 10) into correspond-
ing alcohols, derivatives 17 and 18 were also studied. Most of
the compounds were found to be very potent and selective
COX-2 inhibitors. Compounds 9a,c and 17a,c were selected for
further in vivo studies that highlighted good anti-inﬂammatory
and antinociceptive activities. From tests on bovine articular
cartilage, 9c showed cartilage protective properties owing to the
inhibition of GAG release induced by IL-1β in a concentration-
dependent manner. Finally, compounds 9c and 17c, tested on
human whole blood (HWB), were found to be selective
inhibitors of COX-2. Full ab initio calculations along with
molecular docking, molecular dynamics simulations, and 1H-
and 13C-NMR studies, performed on compounds 6c,d 9c, and
10b, allowed us to assess the right conformation of nitro-
oxyalkyl ester and ether side chains of these molecules within
the COX-2 active site.
Figure 6. Optimized structure of the compounds used in NMR studies performed by means of NWChem (100 steps of RHF, 6-31G*) using CHCl3
as the solvent, mimicking the experimental conditions in which the spectra were recorded and taking into account the NOE constraints resulting
from NMR solutions.
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■ EXPERIMENTAL SECTION
Chemistry. All chemicals used were of reagent grade. Yields refer
to puriﬁed products and are not optimized. Melting points were
determined in open capillaries on a Gallenkamp apparatus and are
uncorrected. Merck silica gel 60 (230−400 mesh) was used for column
chromatography. Merck TLC plates and silica gel 60 F254 were used
for TLC. 1H-NMR spectra were recorded with a Bruker AC 200
spectrometer in the indicated solvent (TMS as internal standard). The
values of the chemical shifts are expressed in ppm, and the coupling
constants (J) are expressed in Hz. Mass spectra were recorded on a
VG 70-250S (EI, 70 eV), a Varian Saturn 3, or a ThermoFinningan
LCQdeca spectrometer. High resolution accurate mass measurements
were recorded by an LTQ-Orbitrap (Thermo Fisher) spectrometer in
positive ESI (for details see Supporting Information). Purity of
compounds 9a−d, 10a−c, 17a−d, and 18a−c was assessed by RP-
HPLC and was found to be higher than 95%. A VWR_Hitachi L-2130
pump system equipped with a VWR_Hitachi L-2400. Merck
LiChroCART 125-4 C18 column was used in the HPLC analysis
with (method A) acetonitrile−water−methanol (50:20:30) or
(method B) methanol−acetonitrile (20:80) as the mobile phase at a
ﬂow rate of 0.7 mL/min. UV detection was achieved at 210 nm.
General Procedure for the Preparation of 1,5-Diaryl-3-(2-
hydroxyethyl)pyrroles (11c,d). A solution of the suitable ethyl
acetate ester24 (1.3 mmol) in dry THF (5 mL) was added dropwise to
a stirred suspension of lithium aluminum hydride (2.8 mmol) in dry
THF (20 mL). After the mixture was stirred for 20 min under nitrogen
atmosphere, the excess of the reducing agent was decomposed by
careful addition of H2O (2 mL). The inorganic material was ﬁltered oﬀ
and washed with THF. The ﬁltrate was dried (Na2SO4) and
evaporated under reduced pressure. The residue, puriﬁed by ﬂash
chromatography (EtOAc/hexane, 6:4 v/v), gave the expected
compound. Compounds 11a,b were resynthesized starting from the
suitable ester, and their spectroscopic and analytical data were
consistent with those that were previously reported.24 The same
procedure was used for the preparation of novel compounds 11c,d.
General Procedure for the Preparation of 1,5-Diaryl-2-
methyl-3-(2-((tetrahydro-2H-2-yloxy)alkoxy)ethyl)-1H-pyrrole
Derivatives (15a−d and 16a−c). Alcohols 11a−c, or 11d (2,7
mmol) and tetrabutyl ammonium bromide (1,35 mmol), cooled to 0
°C were treated with a solution of NaOH 50% p/p (100 mL) and the
suitable 2-(bromoalkoxy)tetrahydro-2H-pyran derivative (10.84
mmol). After being stirred under a nitrogen atmosphere at 70 °C
for 72 h, the mixture was treated with brine (5 mL) and water (20
mL). EtOAc was then added, and the organic extract was washed to
neutrality with water and brine, dried over Na2SO4, ﬁltered, and
concentrated in vacuo. The crude residue, puriﬁed by ﬂash
chromatography, gave the expected compound.
General Procedure for the Preparation of (2-(1,5-Diaryl-2-
methyl-1H-pyrrol-3-yl)alkoxy)alcohols (17a−d and 18a−c). To
a solution of the suitable alcohol 15 or 16 (0.7 mmol) in MeOH (6
mL) pyridinium p-toluenesulfonate (PPTS) (0.1 mmol) was added.
The mixture was then warmed at 55 °C for 1 h while being stirred.
H2O (30 mL) was added, and the mixture was extracted with diethyl
ether (20 mL). The organic layers were washed with brine (20 mL)
and H2O (20 mL), dried over Na2SO4, and ﬁltered. The residue,
obtained after evaporation of the solvent, was puriﬁed by ﬂash
chromatography to give the expected compound.
2-(2-(1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)-
phenyl)-1H-pyrrol-3-yl)ethoxy)ethanol (17c). White solid. Yield
56%. Mp 110−114 °C. 1H-NMR (CDCl3) ppm: 2.01 (broad s, 1H);
2.03(s,3H); 2.76 (t,2H); 2.98 (s,3H); 3.57−3.71 (m,6H); 6.42 (s,1H);
7.02−7.14 (m,6H); 7.61−7.66 (m,2H). MS-ESI: m/z 439 (M + Na+).
General Procedure for the Preparation of 2-(2-(1,5-Diaryl-2-
methyl-1H-pyrrol-3-yl)ethoxy)alkyl Methanesulfonate Deriva-
tives (19a−d and 20a−c). To a solution of the suitable alcohol
17a−d or 18a−c (0.3 mmol) dissolved into CH2Cl2 (10 mL) 4-
(dimethylamino)pyridine (DMAP) (0.03 mmol) and N,N-diisopro-
pylethylamine (DIPEA) (0.5 mmol) were added in sequence. The
solution was cooled at 0 °C, and mesyl chloride (0.6 mmol) was added
dropwise. After being stirred for 3 h at room temperature, the mixture
was treated with H2O (5 mL) and the organic layer washed to
neutrality with saturated NaHCO3 (5 mL) and H2O (5 mL), dried,
ﬁltered, and evaporated to give the expected mesylate as an oil that was
puriﬁed by ﬂash chromatography.
General Procedure for the Preparation of Nitrooxy
Derivatives (9a−d and 10a−c). A solution of the appropriate
mesyl derivative 19a−d or 20a−c (0.3 mmol) in toluene (5 mL) was
treated with tetrabutylammonium nitrate (0.9 mmol), and the mixture
was stirred to reﬂux for 1 h. H2O was added and the mixture extracted
with EtOAc. The organic layer was then washed with brine and H2O,
dried over Na2SO4, ﬁltered and the solvent evaporated in vacuo. The
crude product was puriﬁed by ﬂash chromatography on silica gel to
give the expected compounds.
2-(2-(1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)-
phenyl)-1H-pyrrol-3-yl)ethoxy)ethyl Nitrate (9c). Orange needles
from methanol (yield 70%). Mp 104−105 °C. 1H-NMR (CDCl3) δ
(ppm): 2.03 (s, 3H); 2.75 (t, 2H); 2.98 (s, 3H); 3.63−3.78 (m, 4H);
4.62 (t, 2H); 6.43 (s, 1H); 7.03−7.16 (m, 6H); 7.63−7.67 (m, 2H).
MS-ESI: m/z 485 (M + Na+).
Pharmacology. In Vitro Anti-Inﬂammatory Study. The in vitro
proﬁles of compounds 9a−d, 10a−c, 18a−d, and 19a−c, related to
their inhibitory activity toward both COX-1 and COX-2 isoenzymes,
were evaluated through a cell-based assay employing murine
monocyte/macrophage J774 cell lines. The cell line was grown in
DMEM supplemented with 2 mM glutamine, 25 mM HEPES, 100
units/mL penicillin, 100 μg/mL streptomycin, 10% fetal bovine serum
(FBS), and 1.2% sodium pyruvate. Cells were plated in 24-well culture
plates at a density of 2.5 × 105 cells/mL or in 60 mm diameter culture
dishes (3 × 106 cells per 3 mL per dish) and allowed to adhere at 37
°C in 5% CO2 for 2 h. Immediately before the experiments, the culture
medium was replaced with fresh medium and cells were stimulated as
previously described.51 The evaluation of COX-1 inhibitory activity
was achieved by pretreating cells with the test compounds (10 μM) for
15 min and then incubating them at 37 °C for 30 min with 15 μM
arachidonic acid to activate the constitutive COX. For the compounds
with COX-1 % inhibition higher than 50% (at 10 μM), the cells were
also treated with lower concentrations (0.1−1 μM). At the end of the
incubation, the supernatants were collected for the measurement of
prostaglandin E2 (PGE2) levels by a radioimmunoassay (RIA). To
evaluate COX-2 activity, the cells were stimulated for 24 h with
Escherichia coli lipopolysaccharide (LPS, 10 μg/mL) to induce COX-2,
both in the absence and in the presence of the test compounds (0.01−
10 μM). Celecoxib was used as a reference compound for the
selectivity index. The supernatants were collected for the measurement
of PGE2 by means of RIA.
Ex Vivo Vasorelaxing Activity. All the experimental procedures
were carried out following the guidelines of the European Community
Council Directive 86-609. The eﬀects of the compounds were tested
on isolated thoracic aortic rings of male normotensive Wistar rats
(250−350 g), as previously described.52 After a light ether anesthesia,
rats were sacriﬁced by cervical dislocation and bleeding. The aortae
were immediately excised, freed of extraneous tissues, and the
endothelial layer was removed by gently rubbing the intimal surface
of the vessels with a hypodermic needle. Five millimeter wide aortic
rings were suspended, under a preload of 2 g, in 20 mL organ baths
containing Tyrode solution (composition of saline in mM: NaCl
136.8; KCl 2.95; CaCl2 1.80; MgSO4 1.05; NaH2PO4 0.41; NaHCO3
11.9; glucose 5.5) thermostated at 37 °C and continuously gassed with
a mixture of O2 (95%) and CO2 (5%). Changes in tension were
recorded by means of an isometric transducer (Grass FTO3)
connected with a computerized system (Biopac). After an equilibra-
tion period of 60 min, the endothelium removal was conﬁrmed by the
administration of acetylcholine (ACh) (10 μM) to KCl (30 mM)
precontracted vascular rings. A relaxation of <10% of the KCl-induced
contraction was considered representative of an acceptable lack of the
endothelial layer, while the organs showing a relaxation of ≥10% (i.e.,
signiﬁcant presence of the endothelium) were discarded. From 30 to
40 min after the conﬁrmation of the endothelium removal, the aortic
preparations were contracted by a single concentration of KCl (30
mM), and when the contraction reached a stable plateau, 3-fold
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm301370e | J. Med. Chem. 2013, 56, 3191−32063202
increasing concentrations of compounds (1nM to 10 μM) were added.
Preliminary experiments showed that the KCl (30 mM) induced
contractions remained in a stable tonic state for at least 40 min. The
same experiments were also carried out in the presence of a well-
known GC inhibitor: ODQ 1 μM, which was incubated in aortic
preparations after the endothelium removal was conﬁrmed. The
vasorelaxing eﬃcacy was evaluated as maximal vasorelaxing response
(Emax), expressed as a percentage (%) of the contractile tone induced
by KCl 30 mM. When the limit concentration of 10 μM (the highest
concentration that could be administered) of the tested compounds
did not reach the maximal eﬀect, the parameter of eﬃcacy represented
the vasorelaxing response, expressed as a percentage (%) of the
contractile tone induced by KCl 30 mM, evoked by this limit
concentration. The parameter of potency was expressed as pIC50,
calculated as the negative logarithm of the molar concentration of the
tested compounds evoking a half reduction of the contractile tone
induced by KCl 30 mM. The pIC50 could not be calculated for those
compounds showing an eﬃcacy parameter lower than 50%. The
parameters of eﬃcacy and potency were expressed as the mean ±
standard error for 6−10 experiments. Two-way ANOVA was selected
as statistical analysis, and P < 0.05 was considered representative of
signiﬁcant statistical diﬀerences. The experimental data were analyzed
by a computer ﬁtting procedure (software: GraphPad Prism, version
4.0).
In Vitro Human Whole Blood (HWB) Assay. Compounds 9a
and 17c were also evaluated for COX-1 versus COX-2 selectivity in a
HWB assay. Three healthy volunteers (two females and one male,
aged 29 ± 3 years) were enrolled to participate in the study after its
approval by the Ethical Committee of the University of Chieti, Italy.
Informed consent was obtained from each subject. Compounds 9a
(0.05−150 mM) and 17c (0.05−150 mM) were dissolved in DMSO.
Aliquots of the solutions (2 μL) or vehicle were pipetted directly into
test tubes to give ﬁnal concentrations of 0.1−300 μM in whole blood
samples. To evaluate COX-2 activity, 1 mL aliquots of peripheral
venous blood samples containing 10 IU of sodium heparin were
incubated in the presence of LPS (10 μg/mL) or saline for 24 h at 37
°C, as previously described.53 The contribution of platelet COX-1 was
suppressed by pretreating the subjects with aspirin (300 mg, 48 h)
before sampling. Plasma was separated by centrifugation (10 min at
2000 rpm) and kept at −80 °C until assayed for PGE2 as an index of
monocyte COX-2 activity. Moreover, peripheral venous blood samples
were drawn from the same donors after they had not taken any
NSAID for the 2 weeks preceding the study. Aliquots (1 mL) of whole
blood were immediately transferred into glass tubes and allowed to
clot at 37 °C for 1 h. Serum was separated by centrifugation (10 min at
3000 rpm) and kept at −80 °C until assayed for TXB2. Whole blood
TXB2 production was measured as a reﬂection of maximal platelet
COX-1 activity in response to endogenously formed thrombin.54
Analysis of PGE2 and TXB2. PGE2 and TXB2 concentrations were
measured by previously described and validated radioimmuno-
assays.53,54 Unextracted plasma and serum samples were diluted in
the standard diluent of the assay (0.02 M phosphate buﬀer, pH 7.4)
and assayed in a volume of 1.5 mL at a ﬁnal dilution of 1:50 to
1:30000. [3H]PGE2 or [
3H]TXB2 (3000 cpm, speciﬁc activity of >100
Ci/mmol, 1:100000 dilution) and anti-TXB2 (1:120000 dilution) sera
were used. The least detectable concentration was 1−2 pg/mL for
both prostanoids.53,54
In Vivo Anti-Inﬂammatory and Antinociceptive Study. In
vivo anti-inﬂammatory activity of the title compounds was also
assessed and performed as follows.
Animals. Male Swiss albino mice (23−25g) and Sprague−Dawley
or Wistar rats (150−200 g) were used. Fifteen mice and four rats were
housed per cage. The cages were placed in the experimental room 24 h
before the test for acclimatization. The animals were fed with a
standard laboratory diet and tap water ad libitum and kept at 23 ± 1
°C with a 12 h light/dark cycle, light on at 7 a.m. All experiments were
carried out in accordance with the NIH Guide for the Care and Use of
Laboratory Animals. All eﬀorts were made to minimize animal
suﬀering and to reduce the number of animals used.
Paw-Pressure Test. The paw-pressure test was performed by
inducing an inﬂammatory process by the intraplantar (ipl) carrageenan
(0.1 mL, 1%) administration 4 h before the test The nociceptive
threshold in the rat was determined with an analgesimeter, according
to the method described by Leighton et al.55 Threshold pressure was
measured before and 30, 60, and 120 min after treatment. An arbitrary
cutoﬀ value of 250 g was adopted.
Carrageenan-Induced Edema. The carrageenan-induced paw
edema test was also performed. Rat paw volumes were measured using
a plethysmometer. Four hours after the injection of carrageenan (0.1
mL injection of 1.0%), the paw volume of the right hind paw was
measured and compared with saline/carrageenan treated controls. Rats
received test compounds 3 h 30 min after carrageenan. The results are
reported as paw volume expressed in mL.
Antinociceptive Assay. Antinociceptive activity was determined
by means of an intraperitoneal (ip) injection of a 0.6% acetic acid (10
mL/kg) induced writhing in the mouse abdominal constriction test
according to Koster.56 The number of stretching movements was
counted for 10 min, starting 5 min after acetic acid injection.
Monosodium Iodoacetate Test. An amount of 2 mg of
monosodium iodioacetate (MIA) was solubilized in a volume of 25
μL of saline and injected into the left knee joint of anesthetized rats.
Control rats were treated with an equal volume of saline. Animals
received a repeated administration (14 days twice daily) of 9c or 17c
(20 mg kg−1 po). The administration of MIA induces in rats a
hyperalgesic response to mechanical stimuli that reaches its statistical
signiﬁcance 5 days after administration and persists for 4 weeks. Test
were performed 15−21 days after MIA injection.
Statistical Analysis. Triplicate wells were used for the various
conditions of the treatment in the cell culture assay throughout the
experiments. Results are expressed as the mean of three experiments of
the % inhibition of PGE2 production by test compounds with respect
to control samples. Data ﬁt was obtained using the sigmoidal dose−
response equation (variable slope) (GraphPad software). The IC50
values were calculated with GraphPad Instat, and the data ﬁt was
obtained using the sigmoidal dose−response equation (variable slope)
(GraphPad).
Results from paw-pressure and writhing tests are given as the mean
(SEM, analysis of variance (ANOVA)), followed by Fisher’s PLSD
procedure for post hoc comparison, used to verify the signiﬁcance
between two means. P values lower than 0.05 were considered
signiﬁcant. The data were analyzed by the StatView for the Macintosh
computer program.
Explant Cartilage Cultures. Slices were removed from the
metacarpophalangeal joints of adult bovine animals (18−20 months
old) obtained from the slaughterhouse. Joints were opened under
aseptic conditions, and slices were cut from the exposed articular
surface and washed with Dulbecco’s modiﬁed Eagle medium (DMEM)
containing 500 units/mL of penicillin−streptomycin. Slices were cut
so that each slice was greater than 50 mg in weight. During the harvest,
care was taken not to include cartilage dose to the junction with the
synovium and the calciﬁed cartilage. Slices, about 100 mg quantities,
were then transferred to each well of 24-well tissue culture plates. The
wells were ﬁlled with 1.5 mL of DMEM and incubated at 37 °C in 5%
CO2. The medium was changed at 1 day and 2 days in order to allow
eﬀusion of PG from the cut areas. Assays during this time showed a
progressive decrease in PG (proteoglycan) release that plateaued on
the third day. On the third day, DMEM test solutions were added to
the explants. Culturing was done in nearly all cases with DMEM
without serum in order not to contaminate the culture with Fn-
containing serum or with protease inhibitors. In some experiments,
where optimal cell growth was necessary, DMEM was supplemented
with IGF-1 at a ﬁnal concentration of 20 ng/mL. IGF in serum-free
medium has been shown to promote PG synthesis as optimally as 20%
fetal bovine serum.34 Analysis of GAG release by 1,9-dimethyl-
methylene blue (DMB) assay was performed according to the
colorimetric Farndale method.35
Computational Details. Inhibitor Setup. The structures of the
inhibitors used in the docking simulations were generated by means of
Extensible Computational Chemistry Environment (ECCE) soft-
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ware57 and then geometry-optimized by means of NWChem (100
steps of RHF, 6-31G*). Partial atomic charges RESP were calculated
by means of the NWChem and then used in the following docking
simulations.58 All relevant torsion angles were treated as rotatable
during the docking process, thus allowing a search for the
conformational space.
Enzyme Setup. The COX-2 protein was set up for docking as
follows: polar hydrogens were added by means of ECCE software, and
Kollman united-atom partial charges were assigned.59 The ADDSOL
utility of AutoDock was used to add solvation parameters to the
protein structures, and the grid maps representing the proteins in the
docking process were calculated by means of AutoGrid. The grids, one
for each atom type in the inhibitor plus one for the electrostatic
interactions, were chosen to be large enough to include not only the
cyclooxygenase sites but also a signiﬁcant part of the protein around it.
As a consequence, the dimensions of grid maps were 59 × 45 × 59
points with a grid point spacing of 0.375 Å for COX-2 for all docking
calculations.
Docking Calculations. Compounds 6d and 10b were docked into
the enzymes using AutoDock 4.2.42 Docking simulations of the
compounds were carried out using the Lamarckian genetic algorithm
and through a protocol with an initial population of 300 randomly
placed individuals, a maximum number of 25 million energy
evaluations, a mutation rate of 0.02, a crossover rate of 0.80, and an
elitism value of 1. The pseudo Solis and Wets algorithm with a
maximum of 300 interactions was applied for the local search. Two-
hundred independent docking runs were carried out for each inhibitor,
and the resulting conformations that diﬀered by less than 2.0 Å in
positional root-mean-square deviation (rmsd) were clustered together.
Cluster analysis was performed by selecting the most populated
cluster, which in all cases agreed with the biological aﬃnity data. All
the relevant torsion angles were treated as rotatable during the docking
process, thus allowing a search of the conformational space.
Enzyme Setup. The COX-2 protein was set up for docking as
follows: polar hydrogens were added by means of ECCE software, and
Kollman united-atom partial charges were assigned. The ADDSOL
utility of AutoDock 4.242 was used to add solvation parameters to the
protein structures, and the grid maps representing the proteins in the
docking process were calculated using AutoGrid. The grids, one for
each atom type in the inhibitor plus one for the electrostatic
interactions, were chosen to be large enough to include not only the
cyclooxygenase sites but also a signiﬁcant part of the protein around it.
As a consequence, the dimensions of grid maps were 59 × 45 × 59
points with a grid point spacing of 0.375 Å for COX-2 for all docking
calculations.
Molecular Dynamics. According to Desmond guidelines
(Desmond User Manual, version 3.0; Schrödinger, LLC: New York,
NY, 2011), the representative poses belonging to the best clustered
solutions of the complexes COX-2−6d and COX-2−10b, obtained by
means of docking calculations, were imported into Schrödinger
Maestro molecular modeling environment60 and submitted to Protein
Preparation Wizard workﬂow61 in order to obtain reasonable
complexes used as starting point for molecular dynamics (MD)
simulation protocol. MD simulations were carried out by Desmond 3.0
package62,63 using Maestro molecular modeling environment as
graphical interface.60 The above-mentioned complexes (COX-2−6d
and COX-2−10b; Figures 3 and 4, respectively) were imported in
Maestro and solvated into an orthorhombic box ﬁlled with water,
simulated by TIP3P model.64 OPLS_2005 force ﬁeld65,66 was applied
for MD calculations. Na+ and Cl− ions were added to provide a ﬁnal
salt concentration of 0.15 M in order to simulate physiological
concentration of monovalent ions. (Desmond User Manual, version 3.0;
Schrödinger, LLC: New York, NY, 2011). Constant temperature (300
K) and pressure (1.013 25 bar) were employed with NPT (constant
number of particles, pressure, and temperature) as ensemble class.
RESPA integrator67 was used in order to integrate the equations of
motion, with an inner time step of 2.0 fs for bonded interactions and
nonbonded interactions within the short-range cutoﬀ. Nose−Hoover
thermostats68 were used to keep the constant simulation temperature,
and the Martyna−Tobias−Klein method69 was applied to control the
pressure. Long-range electrostatic interactions were calculated by
particle-mesh Ewald method (PME).70 The cutoﬀ for van der Waals
and short-range electrostatic interactions was set at 9.0 Å. The
equilibration of the system was performed with the default protocol
provided in Desmond, which consists of a series of restrained
minimizations and molecular dynamics simulations used to slowly
relax the system. Consequently, a single trajectory for each complex of
5 ns was calculated.
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